Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.67 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MGAM | O43451 | 4/20 | 0.56 |
| ▸ | SI | P14410 | 4/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7317798 | 0.91 | CSNK2A2 (0.59) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL15515040 | 0.84 | RAB9A (0.63) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL13442817 | 0.83 | MAPT (0.60) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL13244789 | 0.83 | KDM4E (0.56) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL7324615 | 0.83 | CA1 (0.65) | CSNK2A2CSNK2A1KDM4EALDH1A1MAPT | |
| SCHEMBL6539013 | 0.81 | CA1 (0.66) | CSNK2A2CSNK2A1KDM4EALDH1A1MAPT | |
| SCHEMBL7324357 | 0.80 | CSNK2A1 (1.00) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL28529222 | 0.79 | RAB9A (0.65) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL1505311 | 0.79 | RAB9A (0.53) | CSNK2A2CSNK2A1KDM4EALDH1A1MAPT | |
| SCHEMBL22116832 | 0.78 | MAPT (0.51) | CSNK2A2CSNK2A1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139214-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| EP-4289422-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kyushu University, National University Corporation (JP) | 2023-12-13 | — | — | EP | disclosed |
| CN-117042759-A | IL-31 production inhibitor and pharmaceutical composition containing the same | 国立大学法人九州大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023093700-A1 | IMIDAZOTHIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 中国海洋大学 | 2023-06-01 | — | — | WO | disclosed |
| WO-2022168962-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 国立大学法人九州大学 | 2022-08-11 | — | — | WO | disclosed |
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114173772-A | Inhibitors of CD40-CD154 binding | 托尼克斯医药控股公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3952853-A1 | INHIBITORS OF CD40-CD154 BINDING | Tonix Pharmaceuticals Holding Corp. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-108349930-B | Substituted tricycles and methods of use | 艾伯维公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2020210831-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2020-10-15 | — | — | WO | disclosed |
| US-9532989-B2 | Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150374697-A1 | ORGANIC COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-12-31 | — | — | US | disclosed |
| US-9066948-B2 | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130251761-A1 | ORGANIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| EP-2593106-A1 | ORGANIC COMPOUNDS | Rockefeller University (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009688-A1 | ORGANIC COMPOUNDS | ROCKEFELLER UNIVERSITY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | CD40LG, CD40, CD4 | CSNK2A2 4723/4885CSNK2B 4675/4885CSNK2A1 4784/4885 |
| US-20240139214-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | IL36G, IL1RN, IL1B | CSNK2A2 574/4885CSNK2B 348/4885CSNK2A1 378/4885 |
| US-20150374697-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | CSNK2A2 4571/4885CSNK2B 4642/4885CSNK2A1 4566/4885 |
| US-20130251761-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | CSNK2A2 4571/4885CSNK2B 4642/4885CSNK2A1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.